A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted net loss per share is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands, except share and per share amounts)	2025		2024		2025		2024
Basic and diluted net loss per share:
Numerator:
Net loss, basic and diluted	$	(14,733)	$	(11,203)	$	(28,845)	$	(23,314)
Denominator:
Weighted-average shares outstanding, basic and diluted	26,081,273		4,572,010		18,091,478		4,571,377
Net loss per share attributable to common stockholders, basic and diluted	$	(0.56)	$	(2.45)	$	(1.59)	$	(5.10)

As the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods presented. The following potential common stock securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted basis):


	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Stock options issued and outstanding	4,417,157	1,015,502	4,417,157	1,015,502
Restricted stock units outstanding	1,097,209	73,404	1,097,209	73,404
GeneFab Option	1,963,344	1,963,344	1,963,344	1,963,344
Warrants to purchase common stock issued in connection with Series A redeemable convertible preferred stock	31,735,500	—	31,735,500	—
Performance stock units outstanding	—	116,567	—	116,567
Contingent earnout common stock	—	100,000	—	100,000
Unvested early exercised common stock	—	2,954	—	2,954
Total	39,213,210	3,271,771	39,213,210	3,271,771